Literature DB >> 10426607

Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses.

G Morgante1, A la Marca, A Ditto, V De Leo.   

Abstract

OBJECTIVE: To evaluate the ability of two malignancy risk indices (RMI 1 and RMI 2) incorporating menopausal status, serum CA125 level and ultrasound findings, to discriminate a benign from a malignant pelvic mass.
DESIGN: A retrospective study.
SETTING: Department of Obstetrics and Gynaecology, University of Siena, Italy. POPULATION: One hundred and twenty-four women over 30 years of age admitted consecutively between January 1995 and December 1997 for surgical excision of ovarian masses. MAIN OUTCOME MEASURES: The sensitivity, specificity, and positive predictive value of serum CA125, ultrasound findings and menopausal status, separately and combined into the RMI 1 and RMI 2, to diagnose ovarian cancer.
RESULTS: The RMI 1 and RMI 2 were more accurate than menopausal status, ultrasound findings, and CA 125 separately in diagnosing cancer. For all cut off values between 80 and 250, RMI 2 performed better than RMI 1. The RMI 2 at a cut off level of 125 gave a sensitivity of 81%, specificity of 90%, and positive predictive value of 74%.
CONCLUSIONS: We found that RMI 2 was more reliable in discriminating benign and malignant ovarian disease than RMI 1. RMI is a simple method which can be used in gynaecology clinics and less specialised centres.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10426607     DOI: 10.1111/j.1471-0528.1999.tb08318.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  15 in total

1.  Management of a suspicious adnexal mass: a clinical practice guideline.

Authors:  J E Dodge; A L Covens; C Lacchetti; L M Elit; T Le; M Devries-Aboud; M Fung-Kee-Fung
Journal:  Curr Oncol       Date:  2012-08       Impact factor: 3.677

2.  Risk of Malignancy Index (RMI) in Evaluation of Adnexal Mass.

Authors:  Rujuta Javdekar; Nandita Maitra
Journal:  J Obstet Gynaecol India       Date:  2014-10-07

3.  Risk of malignancy index as an evaluation of preoperative pelvic mass.

Authors:  Zinatossadat Bouzari; Shahla Yazdani; Ziba Shirkhani Kelagar; Narges Abbaszadeh
Journal:  Caspian J Intern Med       Date:  2011

4.  Validity of Cancer Antigen-125 (CA-125) and Risk of Malignancy Index (RMI) in the Diagnosis of Ovarian Cancer.

Authors:  Khawla Al-Musalhi; Manal Al-Kindi; Fatma Ramadhan; Thuraya Al-Rawahi; Khalsa Al-Hatali; Waad-Allah Mula-Abed
Journal:  Oman Med J       Date:  2015-11

5.  Comparison of four malignancy risk indices in the detection of malignant ovarian masses.

Authors:  Erhan Aktürk; Rıza Efendi Karaca; Ibrahim Alanbay; Murat Dede; Emre Karaşahin; Müfit Cemal Yenen; Iskender Başer
Journal:  J Gynecol Oncol       Date:  2011-09-28       Impact factor: 4.401

6.  Is Risk Malignancy Index a Useful Tool for Predicting Malignant Ovarian Masses in Developing Countries?

Authors:  Aliya B Aziz; Nida Najmi
Journal:  Obstet Gynecol Int       Date:  2015-06-21

7.  An Evaluation of the Applicability of the Risk of Malignancy Index for Adnexal Masses to Patients Seen at a Tertiary Hospital in Chandigarh, India.

Authors:  Sunny Chopra; Richa Vaishya; Jasbinder Kaur
Journal:  J Obstet Gynaecol India       Date:  2014-07-10

8.  Adnexal masses suspected to be benign treated with laparoscopy.

Authors:  Richard H Demir; Greg J Marchand
Journal:  JSLS       Date:  2012 Jan-Mar       Impact factor: 2.172

9.  Diagnostic Value of the Risk of Malignancy Index (RMI) for Detection of Pelvic Malignancies Compared with Pathology.

Authors:  Mojgan Karimi-Zarchi; Shokouh Paymani Mojaver; Mitra Rouhi; Seyed Hossein Hekmatimoghaddam; Reza Nafisi Moghaddam; Pouria Yazdian-Anari; Soraya Teimoori
Journal:  Electron Physician       Date:  2015-11-20

10.  Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Authors:  György Sölétormos; Michael J Duffy; Suher Othman Abu Hassan; René H M Verheijen; Bengt Tholander; Robert C Bast; Katja N Gaarenstroom; Catharine M Sturgeon; Johannes M Bonfrer; Per Hyltoft Petersen; Hugo Troonen; Gian CarloTorre; Jan Kanty Kulpa; Malgorzata K Tuxen; Raphael Molina
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.